Positive News SentimentPositive NewsNASDAQ:ANIK Anika Therapeutics (ANIK) Stock Forecast, Price & News $18.63 -0.25 (-1.32%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$18.41▼$19.0350-Day Range$16.98▼$25.4552-Week Range$16.54▼$32.51Volume113,383 shsAverage Volume121,779 shsMarket Capitalization$272.56 millionP/E RatioN/ADividend YieldN/APrice Target$23.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Anika Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside26.1% Upside$23.50 Price TargetShort InterestBearish6.83% of Float Sold ShortDividend StrengthN/ASustainability-2.12Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.78) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector799th out of 972 stocksSurgical & Medical Instruments Industry84th out of 101 stocks 3.3 Analyst's Opinion Consensus RatingAnika Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.50, Anika Therapeutics has a forecasted upside of 26.1% from its current price of $18.63.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.83% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Anika Therapeutics has recently increased by 21.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnika Therapeutics has received a 38.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Medical splints", and "Medical screws" products. See details.Environmental SustainabilityThe Environmental Impact score for Anika Therapeutics is -2.12. Previous Next 2.7 News and Social Media Coverage News SentimentAnika Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Anika Therapeutics this week, compared to 3 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.85% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions90.79% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($0.78) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -12.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -12.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anika Therapeutics (NASDAQ:ANIK) StockAnika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Read More ANIK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIK Stock News HeadlinesSeptember 19, 2023 | finance.yahoo.comAnika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual MeetingSeptember 16, 2023 | finanznachrichten.deAnika Therapeutics Inc.: Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 29, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 1, 2023 | finance.yahoo.comDown -20.42% in 4 Weeks, Here's Why You Should You Buy the Dip in Anika (ANIK)August 17, 2023 | finance.yahoo.comCaligan Partners LP Boosts Stake in Anika Therapeutics IncAugust 17, 2023 | marketwatch.comAnika Rotator-Cuff Treatment May Launch in 1Q Following Final FDA ApprovalAugust 17, 2023 | finance.yahoo.comAnika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff RepairsAugust 14, 2023 | msn.comBarrington Research Upgrades Anika Therapeutics (ANIK)September 29, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 11, 2023 | finance.yahoo.comAnika Therapeutics, Inc.'s (NASDAQ:ANIK) Intrinsic Value Is Potentially 92% Above Its Share PriceAugust 10, 2023 | msn.comStephens & Co. Maintains Anika Therapeutics (ANIK) Equal-Weight RecommendationAugust 9, 2023 | finance.yahoo.comQ2 2023 Anika Therapeutics Inc Earnings CallAugust 9, 2023 | finanznachrichten.deAnika Therapeutics Inc.: Anika Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comAdvanced wound care market to grow by USD 4,020.97 million from 2022 to 2027|The increasing volume of surgical procedures drives growth - TechnavioJuly 12, 2023 | finance.yahoo.comAnika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual MeetingMay 31, 2023 | msn.comStephens & Co. Reiterates Anika Therapeutics (ANIK) Equal-Weight RecommendationMay 30, 2023 | finance.yahoo.comAnika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key MilestoneMay 17, 2023 | marketwatch.comHemostatic Agents Market Research | 2023-2030May 16, 2023 | finance.yahoo.comGlobal Osteoarthritis Therapeutics Market to Reach $15.8 Billion by 2030May 16, 2023 | seekingalpha.comANIK Anika Therapeutics, Inc.May 15, 2023 | marketwatch.comInjectable Hyaluronic Acid Fillers Market: 2023-2030 RevenueMay 12, 2023 | marketwatch.comHyaluronic Acid Products Market Price & News with Size ForecastMay 11, 2023 | marketwatch.com2023 Arthritis Pain Injection Drug Market Size and Competitor Analysis in Medical Care Sector | with [104 Pages] and Forecast till 2031May 11, 2023 | markets.businessinsider.comBarrington Keeps Their Hold Rating on Anika Therapeutics (ANIK)May 11, 2023 | marketwatch.com2023-2029 Adhesion Barrier Gel Market Growth Prospects and Countries Analysis | with 85 PagesMay 10, 2023 | finanznachrichten.deAnika Therapeutics Inc.: Anika Reports First Quarter 2023 Financial ResultsMay 9, 2023 | msn.comRecap: Anika Therapeutics Q1 EarningsSee More Headlines Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIK Company Calendar Last Earnings8/08/2023Today9/29/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ANIK CUSIP03525510 CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees345Year Founded1992Price Target and Rating Average Stock Price Forecast$23.50 High Stock Price Forecast$24.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+26.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,860,000.00 Net Margins-13.68% Pretax Margin-16.56% Return on Equity-3.53% Return on Assets-2.90% Debt Debt-to-Equity RatioN/A Current Ratio6.49 Quick Ratio4.67 Sales & Book Value Annual Sales$156.24 million Price / Sales1.74 Cash Flow$0.49 per share Price / Cash Flow37.72 Book Value$19.55 per share Price / Book0.95Miscellaneous Outstanding Shares14,630,000Free Float13,775,000Market Cap$272.56 million OptionableOptionable Beta0.78 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Cheryl Renee Blanchard Ph.D. (Age 59)Pres, CEO & Director Comp: $1.31MMr. Michael L. Levitz (Age 49)Exec. VP, CFO & Treasurer Comp: $710.6kMr. David Colleran J.D. (Age 51)Exec. VP, Gen. Counsel & Corp. Sec. Comp: $664.54kMs. Anne Nunes (Age 54)Sr. VP & COO Mr. Ian W. McLeodVP & Chief Accounting OfficerMr. Mark Namaroff (Age 60)Exec. Director of Investor Relations & Corp. Communications Mr. James ChaseSr. VP of International Sales & MarketingMr. Ben JosephVP of Commercial & Corp. Devel.Ms. Lisa FunicielloVP of HRMore ExecutivesKey CompetitorsCerusNASDAQ:CERSUtah Medical ProductsNASDAQ:UTMDOraSure TechnologiesNASDAQ:OSURAtrionNASDAQ:ATRIAccurayNASDAQ:ARAYView All CompetitorsInstitutional OwnershipAlberta Investment Management CorpBought 8,734 shares on 8/24/2023Ownership: 0.145%Nuveen Asset Management LLCSold 6,560 shares on 8/16/2023Ownership: 0.784%State of Tennessee Treasury DepartmentBought 831 shares on 8/15/2023Ownership: 0.065%Caxton Associates LPSold 1,416 shares on 8/15/2023Ownership: 0.053%Citadel Advisors LLCSold 900 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions ANIK Stock - Frequently Asked Questions Should I buy or sell Anika Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANIK shares. View ANIK analyst ratings or view top-rated stocks. What is Anika Therapeutics' stock price forecast for 2023? 2 analysts have issued twelve-month price objectives for Anika Therapeutics' stock. Their ANIK share price forecasts range from $23.00 to $24.00. On average, they predict the company's stock price to reach $23.50 in the next year. This suggests a possible upside of 26.1% from the stock's current price. View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts. How have ANIK shares performed in 2023? Anika Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, ANIK stock has decreased by 37.1% and is now trading at $18.63. View the best growth stocks for 2023 here. When is Anika Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ANIK earnings forecast. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics, Inc. (NASDAQ:ANIK) released its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.21. The biotechnology company had revenue of $44.30 million for the quarter, compared to analysts' expectations of $40.61 million. Anika Therapeutics had a negative net margin of 13.68% and a negative trailing twelve-month return on equity of 3.53%. What guidance has Anika Therapeutics issued on next quarter's earnings? Anika Therapeutics updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $159.50 million-$163.00 million, compared to the consensus revenue estimate of $161.84 million. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND). What is Anika Therapeutics' stock symbol? Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK." How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Anika Therapeutics' stock price today? One share of ANIK stock can currently be purchased for approximately $18.63. How much money does Anika Therapeutics make? Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $272.56 million and generates $156.24 million in revenue each year. The biotechnology company earns $-14,860,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. How many employees does Anika Therapeutics have? The company employs 345 workers across the globe. How can I contact Anika Therapeutics? Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720. This page (NASDAQ:ANIK) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.